floatz AI
AI-driven scientific diligence for pharma BD, biotech, and life science investors evaluating in-licensing and M&A targets.
Floatz AI targets a real gap — evidence-grade diligence for pharma BD, biotech out-licensing, and life science investors. The Floatz Engine's three layers (self-learning AI agents, a life science knowledge graph, living reports) map directly onto how a diligence question actually gets answered, and claim-to-source referencing plus evidence gap detection are the two features that matter when your recommendation has to survive a deal committee. The trade-off is scope: it is built for in-licensing, M&A, and investment decisions, explicitly not early-stage discovery or trial management. If you evaluate therapeutic assets for a living, this is worth a conversation. If you need a
Verified 6d ago · liveness 50/100 · cite: rightaichoice.com/tools/floatz-ai
- Pharma business development teams
- Biotech firms preparing for out-licensing
- Life science investors
- Corporate venture arms
- Individual academic researchers
- Clinical-stage trial management teams
- End-to-end drug discovery teams
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Floatz if your question is early-stage target discovery or clinical trial operations — this is a diligence tool for in-licensing, M&A, and investment decisions, not a discovery or trial-management platform.
Because pricing is arranged directly with the vendor, budget for a scoping conversation before you know the annual number — hard to slot into a fixed tooling budget without going through that step.
Floatz is positioned for organizations with recurring deal flow — pharma BD groups, biotech firms mid-out-licensing, and life science investors — rather than individuals. If you only need literature review, general AI research tools cost a fraction. If you need evidence-grade diligence that traces every claim to source, the comparison set is specialist diligence platforms, not generic research assistants.
In short
floatz AI — AI-driven scientific diligence for pharma BD, biotech, and life science investors evaluating in-licensing and M&A targets. Best for Pharma business development teams, Biotech firms preparing for out-licensing, Life science investors. Contact Sales pricing.
What's new in floatz AI
Checked 6 days agoAcross the latest 4 updates: 4 news mentions.
AI Tools for Biotech Business Leaders
Floatz published a piece for biotech business leaders on AI tools, aimed at the buyer audience it serves on the BD and out-licensing side.
LVLUP Venture partnership
Floatz announced a partnership with LVLUP Venture, an ecosystem move rather than a product release.
Floatz in Swiss Biotech Day 2026
Floatz appeared at Swiss Biotech Day 2026, signalling continued presence in the European biotech dealmaking circuit.
UPortunity - the ETH Start-up Accelerator
Floatz joined UPortunity, the ETH Start-up Accelerator, adding an academic-ecosystem affiliation alongside its commercial partnerships.
Viability Score
How well maintained and how widely used is floatz AI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Self-learning AI agents for deep science search
- Expert-level reasoning on therapeutic assets
- Life science knowledge graph linking findings and claims
- Evidence evaluated in context rather than in isolation
- Living reports for interactive evidence exploration
- Claim-to-source referencing in every report
- Evidence gap detection for deal diligence
- Portfolio-level standardization across candidates
- Development risk identification before in-licensing
- Benchmarking a candidate against its competitive class
- Surfaces what the data room leaves out
- Workflows for pharma, biotech, and investor sides of a deal
About floatz AI
Floatz AI is a scientific diligence platform built for the three sides of a life science deal: pharma business development, biotech, and investors. Its Floatz Engine runs three layers in sync — self-learning AI agents that do deep science search and expert-level reasoning, a life science knowledge graph that links findings and claims into one evidence system evaluated in context, and living reports you interrogate rather than read once. Every report delivers claim-to-source referencing, evidence gap detection, portfolio-level standardization, and development risks identified, so you can surface what the data room leaves out and benchmark a candidate against its competitive class before you in-license. It is a diligence companion, not a discovery tool: it targets in-licensing, M&A, and investment decisions rather than early-stage target discovery or clinical trial support.
Behind the Verdict
Floatz AI is narrow on purpose, and that is its main argument. Most AI research tools are horizontal — you point them at any question and they return a summary. Floatz instead assumes the question is a deal question: should we in-license this asset, should we invest, and can we defend that call. The Floatz Engine compounds three capabilities. Self-learning AI agents handle deep science search and expert-level reasoning. The life science knowledge graph links findings and claims as one evidence system, which matters because the same finding means something different depending on the claim it supports and the context it sits in — evaluated in isolation, evidence is easy to misread. Living reports then let you explore the knowledge built through that deep research instead of consuming a static PDF. The output layer is where Floatz earns its keep. Claim-to-source referencing means every assertion traces back to where it came from. Evidence gap detection flags what is missing — usually the more useful signal in diligence than what is present. Portfolio-level standardization lets you compare candidates on the same footing rather than on whichever deck was best designed. Development risks are surfaced before in-licensing rather than after. And because the platform covers pharma, biotech, and investor workflows, both sides of a deal can work from the same evidence structure. The vendor's stated promise — surface what the data room leaves out, benchmark the candidate against its competitive class — is exactly the work that currently consumes a diligence team's weeks. Where it does not fit: early-stage drug discovery, clinical trial management, and individual academic literature review are all outside the design. Pricing is contact-based, which the seed material notes slows quick evaluation. The vendor has also been active in the ecosystem — Swiss Biotech Day 2026, an ETH Start-up Accelerator program (UPortunity), and an LVLUP Venture partnership — which signals it is building the relationship network a diligence product needs to be taken seriously. Treat it as a diligence companion with a clear job, and it reads well. Expect it to replace the first pass of a diligence workflow, not the judgment at the end of it.
Researching floatz AI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas floatz AI actually fits — and what changes day-one when you adopt it.
You have a data room for a candidate asset and two weeks before the deal committee. You point the Floatz agents at the science, let the knowledge graph link findings to the claims they support, and read the resulting living report.
Outcome: You walk into the committee with a claim-to-source map, the evidence gaps named, and development risks flagged before signature — rather than a summary you cannot trace.
You use Floatz to build standardized, evidence-backed reports on your own asset and benchmark it against its competitive class.
Outcome: Your asset is presented in the same evidence structure the other side uses, which makes the claims easier for a counterparty diligence team to validate.
You compare two candidates in the same therapeutic area using portfolio-level standardization rather than reading two differently-structured decks.
Outcome: The go/no-go call rests on a like-for-like comparison with the evidence gaps visible on both sides.
Use Cases
- Evaluate an in-licensing opportunity with a living report that carries claim-to-source references and flags evidence gaps.
- Benchmark two competing therapeutic candidates on the same standardized basis before a go/no-go investment call.
- Run diligence on a biotech target by combining data room material with public science to surface development risks.
- Prepare standardized, evidence-backed reports for out-licensing discussions on your own assets.
- Give both sides of a deal a shared evidence structure so the diligence conversation starts from the same claims.
Limitations
- Floatz is purpose-built for in-licensing, M&A, and investment diligence, so it is not designed for early-stage drug discovery or clinical trial support — bring it a deal question, not a target-discovery or trial-ops question.
- Model output quality depends on the underlying training and source data, so claim-to-source referencing is the check to lean on rather than taking a report at face value.
- The platform is positioned for teams with real deal volume; if your work is individual literature review rather than asset evaluation, a general research assistant covers the same ground.
as of 2026-10-02
Verification history
We have re-verified floatz AI 7 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 7 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where floatz AI's pricing actually pencils out — and where peers do it cheaper.
Floatz is positioned for organizations with recurring deal flow — pharma BD groups, biotech firms mid-out-licensing, and life science investors — rather than individuals. If you only need literature review, general AI research tools cost a fraction. If you need evidence-grade diligence that traces every claim to source, the comparison set is specialist diligence platforms, not generic research assistants.
Setup time & first value
How long it actually takes to get something useful out of floatz AI — broken out by persona, not the marketing-page minute.
For a pharma BD or investor team, first value comes when you hand it a live asset question — the platform is built around deal diligence, so starting with a real candidate rather than a test query is the fastest path to a usable report.
Switching to or from floatz AI
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual diligence decks: point the Floatz agents at the same evidence and let claim-to-source referencing replace hand-built citation trails.
- →From generic AI research assistants: keep the same literature questions but get evidence gap detection and portfolio standardization on top of the summary.
- →From a shared drive of PDFs and notes: the knowledge graph links findings and claims that currently sit unconnected across files.
- ↗To a general research assistant if your need shifts to individual literature review rather than asset diligence.
- ↗To a discovery-stage platform if your question moves earlier than in-licensing, M&A, or investment decisions.
- ↗To an internal diligence process if deal volume drops enough that an outside platform no longer earns its place.
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “floatz AI”, and we withheld 6: 6 could not be judged, because “floatz AI” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about floatz AI.
Official links
Tools that pair well with floatz AI
Common stack mates teams adopt alongside floatz AI, with the specific reason each pairing earns its keep.
Evotec
Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.
Insitro
AI-native biotech pairing 20+ petabytes of cellular experiments with population genetics to find causal drug targets
Owkin
Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.
Featured Head-to-Head Comparisons
Floatz Ai vs Codametrix
Choose Floatz AI if you're a drug discovery researcher needing AI-powered target identification from multi-omics data. Choose CodaMetrix if you're a large health system aiming to slash coding costs and denials—its proven 5:1 ROI and #1 KLAS ranking make it the clear leader in medical coding automation. These tools serve entirely different domains, so your choice depends on whether you're in early-stage pharma R&D or healthcare revenue cycle management.
Floatz Ai vs Isomorphic Labs
Choose floatz AI if you need an affordable, self-serve platform for early-stage target discovery with multi-omics integration and exportable reports. Choose Isomorphic Labs only if you are a large pharma company seeking a high-investment, collaborative AI partnership leveraging AlphaFold for lead optimization. For most biotech and academic teams without deep pharma backing, floatz AI is the more accessible and practical choice.
Floatz Ai vs Rapidsos
If you're a drug discovery researcher focused on early-stage target prioritization, floatz AI is purpose-built for you. If you're a public safety agency or enterprise needing real-time emergency intelligence, RapidSOS is the industry standard. These tools serve completely different domains—choose based on your mission.
Alternatives to floatz AI
View all
Frequently Asked Questions
Best-of guides
Topics
Used floatz AI? Help shape our editorial sentiment research.